Key Takeaways
-
DSO offers are built on adjusted EBITDA, not collections. Owners who understand add-backs and replacement-dentist costs can better evaluate any headline number.
-
The EBITDA bridge converts tax-return profit into transferable earnings. Each line reflects a buyer assumption that can often be negotiated or challenged during diligence.
-
Headline enterprise value rarely equals cash at close. Rollover equity, earnouts, debt payoff, and working-capital adjustments can significantly reduce seller proceeds.
-
Multiples move with practice quality. Profitability, payer mix, associate coverage, hygiene production, and facility quality can shift a practice several turns within its range.
-
McLerran & Associates builds a CPA-led, diligence-grade EBITDA analysis up front and represents only the seller to help protect valuation and reduce post-LOI re-trades.
Get a confidential read on your practice’s adjusted EBITDA.
What Is Adjusted EBITDA In A Dental Practice Sale?
DSOs value practices on a multiple of adjusted EBITDA, meaning earnings before interest, taxes, depreciation, and amortization, rather than a simple percentage of collections. Adjusted EBITDA normalizes for how a specific owner runs the practice so buyers can compare practices on an apples-to-apples basis. Adjusted EBITDA for a dental practice is EBITDA after adding back discretionary, personal, and non-recurring expenses, and after subtracting the cost of replacing the owner’s clinical production with a market-rate associate. The result is the transferable operating profit a buyer can reasonably rely on after the seller steps back. A working knowledge of adjusted EBITDA in a dental practice sale can form the foundation for auditing any offer you receive.
The EBITDA multiple method can be a dominant valuation lens in institutional transactions such as DSO, private equity, and strategic acquisitions. Private dentist-to-dentist sales more often use a percentage of collections or seller’s discretionary earnings (SDE, meaning the total economic benefit flowing to a working owner-operator) as the earnings base, according to Private Practice Research’s 2026 valuation framework. The two methods can produce materially different numbers from the same practice. The valuation method chosen can matter as much as the multiple applied to it.
How To Build The EBITDA Bridge From Tax Return To Valuation
The EBITDA bridge is the line-by-line calculation that converts your tax return’s reported profit into the adjusted EBITDA a buyer multiplies to produce a headline offer. Many resources describe the formula, but fewer walk through the arithmetic. Below is a worked example using a hypothetical $2 million-collections general dentistry practice. Notice how the bridge moves from $300,000 of reported net profit to $157,000 of adjusted EBITDA, a 48% reduction that many buyers will apply before pricing your practice.
Every line in this bridge is an assumption the buyer chose. A different buyer can build a different bridge from the same tax return, so controlling the narrative around your EBITDA can materially affect the outcome.
|
Line Item |
Amount |
Notes |
|---|---|---|
|
Reported net profit (after owner W-2 compensation) |
$300,000 |
From practice tax return, after paying the owner a $350,000 salary, with $25,000 of personal expenses run through the practice, per Tenet’s worked example |
|
Add back: Interest expense |
+$18,000 |
Added back to GAAP net income of $120,000, producing a running total of $138,000, a non-operating financing cost and a standard EBITDA add-back, per this EBITDA bridge walkthrough |
|
Add back: Depreciation and amortization |
+$42,000 |
Non-cash charge, standard EBITDA add-back |
|
Starting EBITDA (before normalization) |
$240,000 |
Sum of the three lines above |
|
Add back: Excess owner compensation above market rate |
+$90,000 |
Owner paid $350,000; market associate rate for this production level estimated at $260,000; excess of $90,000 added back. The $260,000 replacement cost stays in the expense base. |
|
Add back: Documented personal expenses run through the practice |
+$180,000 |
Personal vehicle, club membership, personal cell, documented and clearly non-business. |
|
Add back: One-time non-recurring legal and consulting fees |
+$22,000 |
One-time litigation settlement and a non-recurring outside consultant engagement. Buyers will test recurrence across three years of financials. If the same category appears in two of three years, expect a challenge. |
|
Add back: Above-market family payroll |
+$37,000 |
Spouse paid $95,000 for administrative duties a market hire would perform at $58,000; only the $37,000 above-market portion is added back, with documentation required. |
|
Subtotal after add-backs |
$417,000 |
Sum of starting EBITDA plus accepted add-backs |
|
Subtract: Replacement-dentist cost |
−$425,000 |
The loaded cost of a market-rate replacement dentist to replace the owner’s clinical production, per this 2026 guide to dental practice EBITDA add-backs. Buyers benchmark this at roughly 28–32% of adjusted production for a general practitioner, per Practice Worth’s dental valuation methodology. This cost remains in the expense base after the owner leaves and cannot be added back. |
|
Adjusted EBITDA |
$157,000 |
The transferable operating profit a buyer prices on. In this adjusted EBITDA walkthrough, the bridge starts with reported EBITDA of 1,000 and, after adding a one-off legal settlement of 80 and owner salary above market of 60, and subtracting a one-off insurance recovery of 50 and lost customer run-rate of 90, arrives at adjusted EBITDA of 1,000. |
Notice how far adjusted EBITDA can sit from reported net profit, and how each line is a negotiable assumption. That gap matters because every dollar of EBITDA is multiplied by the buyer’s multiple. At a 7x multiple, a $50,000 EBITDA dispute translates to a $350,000 purchase price difference, and the leverage grows with the multiple. Every $100,000 of legitimate, documented EBITDA add-backs translates to $700,000 of enterprise value at a 7x multiple, so careful documentation can work in your favor.
McLerran & Associates is a dental-only sell-side advisor and advocate that builds a CPA-led, diligence-grade EBITDA analysis up front so the valuation has a stronger chance of holding under buyer scrutiny and the deal is less likely to be re-traded later. McLerran represents only the seller, never the buyer, and has evaluated more than 10,000 dental practices. That depth means the firm can often anticipate which add-backs hold and which collapse in diligence before the buyer’s quality-of-earnings team ever opens the file.
Once you understand the bridge, the next question is what the resulting adjusted EBITDA can translate to in the market.
How Much Are Dental Practices Selling For?
Dental practices can sell across a wide range of values driven by adjusted EBITDA, practice size, profitability, associate coverage, payer mix, specialty, and buyer competition. The headline enterprise value rarely matches cash proceeds. Rollover equity, earnouts, debt payoff, taxes, and working-capital adjustments can materially reduce what a seller actually receives at close. The DSO premium over private-buyer valuations can commonly be 40–80% for practices that clear institutional-buyer requirements, and the structure of the deal can determine how much of that premium reaches the seller’s bank account.
For a deeper look at current valuation ranges by practice size and buyer type, see Dental Practice Valuation For A DSO Sale: 2026 Guide. But ranges are only the starting point, and the more useful question is what moves a practice within its range.
How To Move Your Practice From A Low Multiple To A High One
Multiples behave like levers that respond to the specific characteristics of a practice. The same $2 million-adjusted-EBITDA practice could reasonably clear at materially different multiples depending on payer mix, referral source concentration, provider retention, and sub-segment. The following factors can influence where a practice lands within its applicable range, and the first three, profitability, owner independence, and hygiene production, can be some of the main factors institutional buyers weigh.
-
Profitability and margin. EBITDA margin above roughly 20% of collections can signal operational discipline that earns a price premium. Two practices collecting the same revenue can differ by hundreds of thousands of dollars in adjusted EBITDA depending on overhead structure.
-
Associate coverage and owner independence. When earnings are founder-dependent or operational durability is uncertain, buyers may shift consideration away from guaranteed cash at close into rollover equity, earnouts, or holdbacks. Practices where the owner produces a large share of clinical revenue can face valuation haircuts because a buyer cannot underwrite production that walks out the door with the seller. Associate-led production with the owner below a meaningful share of chair time can support the upper end of the applicable range.
-
Hygiene production. Recurring hygiene production is a key EBITDA-quality signal, ideally representing 25 to 33 percent of total production, and can be worth an estimated additional fraction of a turn on the multiple.
-
Payer mix. Payer mix can be one of the largest single multiple drivers in dental M&A, with fee-for-service revenue potentially worth several multiple turns more than equivalent Medicaid or HMO earnings. Heavy Medicaid concentration can compress multiples and narrow the buyer pool significantly.
-
Scale and number of locations. Three practices might each be priced at a lower multiple individually. Combined into one group with a higher total EBITDA, the same earnings can sit in a higher multiple band. Multi-location clusters can begin commanding emerging-platform pricing once shared management infrastructure is in place.
-
Team stability and retention. Associate and hygienist retention can be a primary decision driver for DSO acquirers. Buyer confidence and sale price can increase when key staff plan to remain post-close.
-
Technology and facility quality. Practices without cone beam CT and intraoral scanners have consistently landed in the lower half of size-matched valuation ranges, as digital dentistry investment has shifted from a nice-to-have to a table-stakes requirement.
-
Specialty. Specialty shapes buyer demand and valuation. Oral and maxillofacial surgery can command the highest multiples and remains among the fastest-consolidating segments; orthodontics and pediatric dentistry can draw strong DSO interest; general dentistry still earns aggressive, near-all-time-high valuations; and lighter-demand specialties tend to sit at the lower end of the range.
How DSO Buyer Competition Can Affect Your Practice Value explores how creating competitive tension among buyers can move a practice toward the top of its applicable range.
See which multiple drivers your practice is missing.
How To Read Your DSO Deal Structure: Cash, Equity, And Earnout
The headline enterprise value and the cash a seller receives at close can be materially different numbers. A clear view of DSO deal structure, including cash, equity, and earnout, can be essential to evaluating any offer.
A typical DSO deal structure can run roughly 60–75% cash at close, 15–30% rollover equity, and 5–15% earnout tied to retained EBITDA over 12–36 months, with a working-capital adjustment trued up at closing. As much as 40% of a DSO deal can be paid in equity rather than cash, meaning the owner is effectively buying stock in the DSO and should underwrite the buyer like an investment.
Rollover equity can sit at two different levels, and the distinction matters:
-
Joint-venture (JV) level equity tracks only the seller’s own practice locations, pays through distributions, and carries a higher floor but a lower ceiling.
-
Holding-company level equity tracks the entire DSO platform, pays at a future recapitalization, and carries a higher ceiling, with a floor that can be zero if the platform underperforms or the preferred capital stack consumes all proceeds.
The letter of intent frequently does not specify which level the rollover equity sits at, so sellers should ask before signing.
The earnout metric determines whether any contingent payment is actually made, and it matters more than the earnout percentage. The same practice, in the same year, can earn the full earnout amount or nothing at all depending on two definitions in the agreement, for example, whether the target is measured on collections, production, or EBITDA including or excluding the buyer’s management fee.
The table below illustrates how a headline enterprise value can reconcile to a materially different after-tax proceeds figure. This is a simplified illustration; actual outcomes depend on deal-specific terms, tax structure, and advisor guidance. Consult your tax advisor for guidance specific to your situation.
|
Line Item |
Amount |
Notes |
|---|---|---|
|
Headline enterprise value |
$2,000,000 |
The number in the DSO’s offer letter |
|
Less: Rollover equity |
−$392,000 |
In this illustration, rollover equity is $392,000, which is 20 percent of the $1.96M headline price, paid in units of the buyer’s parent company instead of cash. Illiquid; realized only at a future DSO recapitalization, typically 3–7 years away. Rollover equity converts to cash only at the DSO’s future recapitalization or sale, which is not guaranteed. |
|
Less: Earnout |
−$200,000 |
In the illustrative $2,000,000 DSO offer, the earnout is about 10% of enterprise value, or $200,000, which the seller collects only if the practice hits its EBITDA or production targets over the earnout window |
|
Cash at close (before adjustments) |
$1,400,000 |
The portion paid on closing day |
|
Less: Debt payoff (equipment loans, lines of credit) |
−$120,000 |
Net debt subtracted from proceeds at close |
|
Less: Working-capital adjustment |
−$30,000 |
True-up for accounts receivable, prepaid expenses, and patient credits relative to the agreed peg |
|
Less: Escrow / holdback |
−$98,000 |
In this illustration, the escrow/holdback is 5% of the price, $98,000, released in twelve to eighteen months if no claim is made. |
|
Net cash received at close |
$1,200,000 |
In this illustration, net cash received at close is $1,200,000, after the $98,000 escrow, $45,000 note, and $29,000 of transaction costs, but before taxes. |
|
Tax note |
Varies |
For tax-allocation purposes, 76% or more of a dental practice’s purchase price typically flows to goodwill, which can be taxed at long-term capital gains rates rather than the ordinary income rates that apply to equipment recapture and non-compete payments. Consult your tax advisor. |
Talk through your DSO deal structure with a sell-side advisor.
How To Pressure-Test A DSO Offer Before You Sign
Sellers can reconstruct the buyer’s EBITDA bridge and audit the offer by asking targeted questions instead of accepting it at face value. Before signing a letter of intent, consider asking the buyer the following:
-
Which add-backs did you accept and which did you reject, and why?
-
How did you normalize owner compensation, and what replacement-dentist cost did you assume?
-
How is the earnout calculated, what is the target metric, and is the earnout pro-rata (so a near-miss still pays most of the amount) or binary?
-
What happens to rollover equity if the DSO underperforms or the recapitalization is delayed?
-
Does the rollover equity sit at the JV level or the holding-company level?
-
What working-capital adjustment applies at close, and how is the peg defined?
A seller who talks to only one DSO sees one set of assumptions, with no competitive tension to push the price up. Practices taken to market through a structured multiple-buyer solicitation process can receive final sale values averaging significantly above initial unsolicited offers. That is why a structured multiple-buyer solicitation process matters. A competitive process among vetted buyers reveals the real market and creates the tension that can move both price and terms. For a detailed walkthrough of the process, see 9 Steps To Sell Your Dental Practice To A DSO In 2026 and How To Vet DSO Partners Before Selling Your Dental Practice. Those questions matter because the answers differ from buyer to buyer, which is the subject of the next section.
Why The Same Practice Gets Different Numbers From Different Buyers
Valuation reflects a set of buyer assumptions rather than a universal formula. Different DSOs and private equity buyers can build different bridges and apply different multiples to the same practice, because each applies its own add-back assumptions, growth thesis, and integration synergies. This dynamic explains why competitive tension can matter and why a sell-side advisor who helps control the narrative around EBITDA, rather than letting the buyer set the anchor, can influence the outcome.
McLerran & Associates works both the private-buyer and DSO paths in roughly equal measure, so owners can see a side-by-side valuation of their worth in both markets before deciding. The firm’s track record reflects this approach: roughly 2,000 successful practice sales, approximately $2 billion in closed transaction volume, a structured auction-like bid process typically lasting 45–60 days and generating around 10 offers, and a client transaction rate of roughly 85–90% versus an industry norm closer to 35–40%.
See your practice valued in both the private-buyer and DSO markets.
Frequently Asked Questions
How Is Adjusted EBITDA Calculated For A Dental Practice?
Adjusted EBITDA starts with reported net income from the practice tax return, then adds back interest, taxes, depreciation, and amortization to arrive at base EBITDA. From there, the analysis layers in add-backs for discretionary, personal, and non-recurring expenses and adds back the categories shown in the bridge above, including excess owner compensation, personal expenses, above-market family payroll, and one-time costs. Finally, the cost of replacing the owner’s clinical production with a market-rate associate is subtracted. The result is the transferable operating profit a DSO buyer will multiply to produce a headline offer. Every line is a documented assumption, and every dollar of accepted add-back increases enterprise value by that dollar multiplied by the applicable multiple.
What Add-Backs Do DSO Buyers Typically Accept?
Buyers can accept add-backs that are documented, clearly non-recurring, and genuinely owner-specific. Common accepted categories include the portion of owner compensation above a defensible market rate for the clinical work performed (only the excess above replacement cost), documented personal expenses such as personal vehicle costs, club memberships, and personal insurance premiums, one-time non-recurring costs such as a litigation settlement or emergency equipment repair that is isolated across multiple years of financials, and above-market family payroll, where only the difference between actual pay and market pay is addable. Buyers typically reject planned future expenses, recurring operational costs that would continue under new ownership, and any add-back that lacks contemporaneous documentation. An aggressive add-back schedule that collapses in diligence can cause buyers to re-examine everything already accepted, which can be more damaging than a conservative schedule that holds.
Why Is The Replacement-Dentist Cost Subtracted From EBITDA?
A DSO cannot underwrite production revenue that walks out the door with the seller. After the owner leaves or reduces clinical involvement, someone must perform the clinical work, and that associate costs money. The replacement-dentist cost is the loaded expense of hiring a market-rate associate to produce what the owner currently produces, typically benchmarked at the 28–32% of adjusted production cited earlier. This cost is not an add-back; it is the expense that remains in the business after the transition. Failing to subtract it can overstate the transferable earnings a buyer is actually acquiring, and buyers’ quality-of-earnings teams will apply it regardless of whether the seller’s presentation includes it.
Are DSO Deals All Cash?
Almost never. DSO deals are almost always a combination of cash at close, rollover equity, and an earnout, with the cash portion typically in the 60–75% range discussed above. The balance is often split between rollover equity held at either the JV or holding-company level and an earnout tied to post-close performance targets over 12–36 months. Sellers are effectively buying stock in the DSO with the equity portion and can benefit from evaluating the buyer’s financial health, management team, and private equity backing as carefully as any investment. Private-buyer (doctor-to-doctor) sales, by contrast, typically pay 100% cash at closing.
What Is Rollover Equity, And How Does JV-Level Differ From Holding-Company-Level?
Rollover equity is the portion of a DSO deal paid in ownership interest rather than cash. It is illiquid, and it converts to cash only when the DSO recapitalizes or sells, which may be three to seven years away and is not guaranteed. JV-level equity tracks only the seller’s own practice locations and pays through distributions, offering a higher floor but a lower ceiling. Holding-company equity tracks the entire DSO platform and pays at a future recapitalization, offering a higher ceiling, with a floor that can be zero if the platform’s preferred capital stack consumes all proceeds before common equity participates. The letter of intent frequently does not specify which level applies, so sellers can benefit from clarifying this before signing. McLerran & Associates models both structures across multiple time horizons so clients can compare real after-tax outcomes before choosing.
When Should I Get A Practice Valuation?
Earlier planning can create more options. Practice owners who begin formal transition planning five to ten years before a target exit can achieve higher realized values and smoother transitions than those who begin within three years. A valuation done two or more years before a planned sale gives time to address value detractors, such as owner dependence, hygiene production gaps, payer mix, and technology, that can move a practice from the low end to the high end of its applicable multiple range. McLerran & Associates provides a comprehensive, CPA-led valuation as the foundation of every engagement, and will update the valuation at no charge a year later for owners who are not yet ready to proceed.
Get your DSO valuation questions answered on a confidential call.
Conclusion: Audit The Offer And Control The Math
A DSO offer is a math problem a seller can reconstruct. The headline number is built on a set of buyer assumptions, including add-backs accepted or rejected, a replacement-dentist cost applied, and a multiple chosen, and every one of those assumptions is open to review. Sellers who understand the bridge can negotiate from a position of knowledge and treat the buyer’s anchor as one data point rather than a fixed starting point.
McLerran & Associates is the dental-only sell-side advisor and advocate that builds the CPA-led, diligence-grade EBITDA analysis up front, creates competition among a vetted pool of buyers, and helps manage the narrative around your EBITDA through every stage of the transaction. The firm represents only the seller, never the buyer, and its roughly 85–90% transaction rate reflects what can happen when the math is done carefully before the deal goes to market.
Put a sell-side advisor in your corner before you sign.
